Diagnostic performance of β-(1→3)-D-glucan, two <i>Candida</i> antigen, and five anti-<i>Candida</i> antibody assays in ICU patients with sepsis and high risk for invasive candidiasis: a secondary endpoint of the CandiSep randomized clinical trial.

J Clin Microbiol · 2026 · PMC13170172 · PMID 42023876

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Only Platelia-Ab in patients with candidemia showed a trend toward a higher AUROC compared to some of the other antibody assays (Serion-IgG and Serion-IgA).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Diagnostic performance of β-(1→3)-D-glucan, two &lt;i&gt;Candida&lt;/i&gt; antigen, and five anti-&lt;i&gt;Candida&lt;/i&gt; antibody assays in ICU patients with sepsis and high risk for invasive candidiasis: a secondary endpoint of the CandiSep randomized clinical trial.

The sentences

Diagnostic performance of β-(1→3)-D-glucan, two <i>Candida</i> antigen, and five anti-<i>Candida</i> antibody assays in ICU patients with sepsis and high risk for invasive candidiasis: a secondary endpoint of the CandiSep randomized clinical trial.